MDS Pharma Services

INC Research Plans to Acquire Late Stage Division of MDS for $50M

Tuesday, June 2, 2009 07:00 AM

Raleigh, N.C.-based contract research organization (CRO) INC Research entered into an agreement to acquire the phase II through IV operations of MDS Pharma Services, the clinical development division of MDS, for $50 million.

More... »

MDS Pharma's First Quarter Revenues Down 12%

Friday, March 13, 2009 08:00 AM

Revenues for contract research organization (CRO) MDS Pharma Services continue to fall as a result of client delays in late-stage research and decreased activity in preclinical and bioanalytical services.

More... »

MDS Pharma Revenues Continue to Fall

Thursday, December 18, 2008 09:41 AM

Canadian life science company MDS, the parent company of King of Prussia, Pa.-based MDS Pharma Services, released fourth quarter results reflecting another disappointing quarter for its embattled contract research organization (CRO) division. Net revenues for MDS Pharma were $112 million, down 9% from the same quarter last year.

More... »

MDS Pharma Profits Sink in 3rd Quarter

Thursday, September 4, 2008 01:33 PM

Canadian life science company MDS, the parent company of King of Prussia, Pa.-based CRO MDS Pharma Services, reduced its fiscal 2008 revenue and profit outlook after reporting lower than expected third-quarter results in its contract research division. The company now expects fiscal 2008 revenue to be in the range of $1.23 billion to $1.25 billion, down from its previous forecast of $1.25 billion to $1.29 billion.

More... »

MDS Cuts 210 Staff in North America

Friday, July 18, 2008 01:45 PM

MDS has become the second pharmaceutical services company in as many weeks to report a round of layoffs. Toronto-based MDS has slashed 210 jobs from its North American workforce, representing 4% of MDS’s 5,500 worldwide employees. The company stated that 75% of the lay offs will come from its MDS Pharma Services (contract research) division with the remainder from its Analytical Technologies (medical equipment manufacturing) group. MDS cited that the action will result in third quarter charges of $18 million and $10 million in write downs at its Pharma Services laboratory based in Montreal. Company shares rose 1.8 per cent, or 26 cents, to $14.85 in trading on the Toronto Stock Exchange.  MDS is scheduled to release its third quarter fiscal 2008 earnings on September 4, 2008.

More... »

MDS Pharma Services Top CRO in CenterWatch's 2006 European Site Survey

Friday, June 9, 2006 03:33 PM

The CenterWatch 2006 European Investigative Site Survey marks the fifth time CenterWatch has surveyed investigative sites—those front-line researchers conducting clinical trials in Europe. MDS Pharma earned the top score for contract research organizations, improving from third place in the 2004 survey.

More... »